{"analyses":[{"ciLowerLimit":"0.80","ciPctValue":"95","ciUpperLimit":"1.06","estimateComment":"Temozolomide events (progressions/deaths) = 401. Dacarbazine events (progressions/deaths) = 398.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2663","paramType":"Hazard Ratio (HR)","paramValue":"0.92","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.23","upperLimit":"2.43","value":"2.30"},{"groupId":"OG001","lowerLimit":"2.14","upperLimit":"2.27","value":"2.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"429"},{"groupId":"OG001","value":"430"}],"units":"Participants"}],"description":"Progression free survival was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (\"7 days on / 7 days off\" continuously)","id":"OG000","title":"Temozolomide"},{"description":"dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks","id":"OG001","title":"Dacarbazine"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat Population","reportingStatus":"POSTED","timeFrame":"Treatment continued until disease progression or unacceptable toxicity. Patients will be followed for survival.","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}